文献速递细菌感染、耐药与抗菌药物

德拉沙星对甲氧西林、万古霉素、达托霉素或利奈唑胺敏感性降低或耐药的金黄色葡萄球菌的活性

Delafloxacin activity against Staphylococcus aureus with reduced susceptibility or resistance to methicillin, vancomycin, daptomycin or linezolid.
PubMed 文献 · J Antimicrob Chemother · 2020-01-01

该研究测定了德拉沙星对比左氧氟沙星、万古霉素、达托霉素和利奈唑胺对110株MRSA血流分离株、15株VRSA、35株VISA、40株DNSSA和6株LRSA的体外活性。德拉沙星对MRSA血流分离株MIC90为1 mg/L、敏感率68%,对VISA、VRSA和DNSSA的MIC90分别为1、4和1 mg/L,LRSA均不敏感。结论认为德拉沙星对近期MRSA血流分离株、VISA、VRSA和DNSSA的活性优于左氧氟沙星。

要点

  • 德拉沙星对MRSA血流分离株MIC90为1 mg/L,敏感率68%。
  • 对VISA、VRSA、DNSSA的MIC90分别为1、4、1 mg/L,敏感率分别为40%、7%、38%。
  • LRSA对德拉沙星均不敏感;对左氧氟沙星MIC≥8 mg/L的MRSA血流分离株敏感率为36.4%。

核心结论

  • 德拉沙星对近期MRSA血流分离株、VISA、VRSA和DNSSA的活性优于左氧氟沙星,对社区常见血流分离株活性良好。

研究设计与样本

  • 采用CAMHB微量稀释法按CLSI指南测定MIC,德拉沙星判读用FDA折点,其他抗生素用CLSI折点,并进行分子标记PCR检测。
  • 测试菌株包括110株MRSABIs、15株VRSA、35株VISA、40株DNSSA和6株LRSA。

主要发现

  • 德拉沙星对MRSABIs的MIC90为1 mg/L,敏感率68%。
  • 对VISA的MIC90为1 mg/L、敏感率40%,对VRSA的MIC90为4 mg/L、敏感率7%,对DNSSA的MIC90为1 mg/L、敏感率38%。
  • 6株LRSA均对德拉沙星不敏感。
  • 对基因型SCC IVa的MRSA血流分离株,德拉沙星活性覆盖94%。
  • 对左氧氟沙星MIC≥8 mg/L(提示QRDR多重突变)的55/110株MRSABIs,德拉沙星MIC90为1 mg/L,敏感率36.4%。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Delafloxacin is a recently approved anionic fluoroquinolone antibiotic with broad-spectrum activity against Gram-positive and Gram-negative organisms. The drug has been approved for patients with acute bacterial skin and skin structure infections including those caused by MRSA. There are limited data available against MRSA blood isolates (MRSABIs), vancomycin-intermediate strains (VISA), vancomycin-resistant strains (VRSA), daptomycin-non-susceptible strains (DNSSA) and linezolid-resistant Staphylococcus aureus (LRSA). METHODS: Antimicrobial activity of delafloxacin, levofloxacin, vancomycin, daptomycin and linezolid was determined against 110 MRSABIs, 15 VRSA, 35 VISA, 40 DNSSA and 6 LRSA. Microdilution testing using CAMHB was used to determine MIC according to CLSI guidelines. FDA breakpoints were used to determine delafloxacin susceptibility, and CLSI breakpoints were used for all other antibiotics. PCR testing for molecular markers was performed. RESULTS: Delafloxacin demonstrated activity against MRSABIs with an MIC90 of 1 mg/L and 68% susceptibility. Against the other groups the MIC90 and susceptibility were 1 mg/L and 40%, respectively, for VISA, 4 mg/L and 7% for VRSA and 1 mg/L and 38% for DNSSA. None of the LRSA isolates was susceptible to delafloxacin. Delafloxacin was active against 94% of MRSA blood isolates that were genotype SCC IVa. For MRSABIs with a levofloxacin MIC ≥8 mg/L (55/110), suggesting multiple mutations in the QRDR, delafloxacin MIC90 was 1 mg/L with a 36.4% susceptibility rate. CONCLUSIONS: Delafloxacin demonstrates superior activity to levofloxacin against recent MRSA blood isolates, VISA, VRSA and DNSSA, and demonstrates good activity against blood isolates most commonly found in the community.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Saravolatz LD, Pawlak JM, Wegner C, et al. Delafloxacin activity against Staphylococcus aureus with reduced susceptibility or resistance to methicillin, vancomycin, daptomycin or linezolid. J Antimicrob Chemother. 2020. PMID: 32542310. doi:10.1093/jac/dkaa209

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。